How Linked Real-World Data Improves Therapeutic Development for Cancer Patients
Oncology is a complex therapeutic area owing to the heterogeneity of cancer types, diversity of patient responses, and diverse treatment options available. Drug development trials in oncology are numerous, but because of incomplete data and small sample sizes, they sometimes fail to perform in real-world settings. Clinical trials prove impractical for certain disease subsets related to cancer. The associated costs and the long lag time to obtain results in clinical trials add to the existing challenges. All this reflects the gaps in existing research methods. To meet these challenges, there is an increased need for real-world evidence (RWE) for oncology drug research and development (R&D). RWE provides useful information through the extrapolation of data from real-world sources such as electronic health records, claims, and patient registries. Regulatory bodies, such as the FDA and EMA, have also acknowledged the importance of RWE in supporting the drug development process. RWE is ...